Chitosan nanoplatform for the co-delivery of palbociclib and ultra-small magnesium nanoclusters : dual receptor targeting, therapy and imaging
© The author(s)..
Theranostic nanoparticles have gained significant attention in cancer diagnosis and therapy. In this study, estrone (ES) and folic acid (FA) functionalized single and dual receptor targeted theranostic chitosan nanoparticles were developed for breast cancer imaging and therapy. These nanoparticles (NPs) were loaded with palbociclib (PB) and ultra-small magnesium nanoclusters (UMN). The developed nontargeted theranostic NPs (PB-UMN-CS-NPs), estrogen receptor targeted theranostic NPs (PB-UMN-CS-ES-NPs), folate receptor targeted theranostic NPs (PB-UMN-CS-FA-NPs), and dual targeted theranostic NPs (PB-UMN-CS-ES-FA-NPs) have particle sizes of 178.4 ± 1.21 nm, 181.6± 1.35 nm, 185.1± 1.33 nm, and 198.2± 1.43 nm with surface charges of +19.02± 0.382 mV, +13.89±0.410 mV, +16.72±0.527 mV and +15.23±0.377 mV, respectively. Cytotoxicity studies on estrogen receptor (ER) and folate receptor (FR) expressing breast cancer cells revealed that dual-targeted theranostic NPs (PB-UMN-CS-FA-ES-NPs) were more effective, inhibiting cell growth by 54.17 and 42.23 times in MCF-7 and T-47D cells compared to free PB, respectively. Additionally, developed NPs were capable of inhibiting the cell cycle progression of MCF-7 cells from the G1 phase to the S phase more efficiently compared to free PB. Ultrasound and photoacoustic (USG/PA) imaging demonstrated that dual targeted theranostic NPs were capable of effectively reducing hypoxic tumor volume and significantly suppressing tumor vascularity compared to free PB, nontargeted, FR targeted and ER targeted NPs. Moreover, in vivo optical imaging demonstrated tumor specific accumulation of the dual-targeted theranostic NPs. Furthermore, in vitro hemocompatibility and histopathological studies confirmed the biocompatibility of developed nanoformulations.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
---|---|
Enthalten in: |
Nanotheranostics - 8(2024), 2 vom: 12., Seite 179-201 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mehata, Abhishesh Kumar [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 07.03.2024 Date Revised 07.03.2024 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.7150/ntno.94364 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369345738 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369345738 | ||
003 | DE-627 | ||
005 | 20240307232715.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240306s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.7150/ntno.94364 |2 doi | |
028 | 5 | 2 | |a pubmed24n1319.xml |
035 | |a (DE-627)NLM369345738 | ||
035 | |a (NLM)38444739 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mehata, Abhishesh Kumar |e verfasserin |4 aut | |
245 | 1 | 0 | |a Chitosan nanoplatform for the co-delivery of palbociclib and ultra-small magnesium nanoclusters |b dual receptor targeting, therapy and imaging |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.03.2024 | ||
500 | |a Date Revised 07.03.2024 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The author(s). | ||
520 | |a Theranostic nanoparticles have gained significant attention in cancer diagnosis and therapy. In this study, estrone (ES) and folic acid (FA) functionalized single and dual receptor targeted theranostic chitosan nanoparticles were developed for breast cancer imaging and therapy. These nanoparticles (NPs) were loaded with palbociclib (PB) and ultra-small magnesium nanoclusters (UMN). The developed nontargeted theranostic NPs (PB-UMN-CS-NPs), estrogen receptor targeted theranostic NPs (PB-UMN-CS-ES-NPs), folate receptor targeted theranostic NPs (PB-UMN-CS-FA-NPs), and dual targeted theranostic NPs (PB-UMN-CS-ES-FA-NPs) have particle sizes of 178.4 ± 1.21 nm, 181.6± 1.35 nm, 185.1± 1.33 nm, and 198.2± 1.43 nm with surface charges of +19.02± 0.382 mV, +13.89±0.410 mV, +16.72±0.527 mV and +15.23±0.377 mV, respectively. Cytotoxicity studies on estrogen receptor (ER) and folate receptor (FR) expressing breast cancer cells revealed that dual-targeted theranostic NPs (PB-UMN-CS-FA-ES-NPs) were more effective, inhibiting cell growth by 54.17 and 42.23 times in MCF-7 and T-47D cells compared to free PB, respectively. Additionally, developed NPs were capable of inhibiting the cell cycle progression of MCF-7 cells from the G1 phase to the S phase more efficiently compared to free PB. Ultrasound and photoacoustic (USG/PA) imaging demonstrated that dual targeted theranostic NPs were capable of effectively reducing hypoxic tumor volume and significantly suppressing tumor vascularity compared to free PB, nontargeted, FR targeted and ER targeted NPs. Moreover, in vivo optical imaging demonstrated tumor specific accumulation of the dual-targeted theranostic NPs. Furthermore, in vitro hemocompatibility and histopathological studies confirmed the biocompatibility of developed nanoformulations | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a breast cancer, dual receptor targeting | |
650 | 4 | |a chitosan nanoparticles | |
650 | 4 | |a optical and ultrasound/photoacoustic imaging, theranostics | |
650 | 7 | |a palbociclib |2 NLM | |
650 | 7 | |a G9ZF61LE7G |2 NLM | |
650 | 7 | |a Chitosan |2 NLM | |
650 | 7 | |a 9012-76-4 |2 NLM | |
650 | 7 | |a Magnesium |2 NLM | |
650 | 7 | |a I38ZP9992A |2 NLM | |
650 | 7 | |a Folic Acid |2 NLM | |
650 | 7 | |a 935E97BOY8 |2 NLM | |
650 | 7 | |a Receptors, Estrogen |2 NLM | |
650 | 7 | |a Piperazines |2 NLM | |
650 | 7 | |a Pyridines |2 NLM | |
700 | 1 | |a Singh, Virendra |e verfasserin |4 aut | |
700 | 1 | |a Vikas |e verfasserin |4 aut | |
700 | 1 | |a Srivastava, Prachi |e verfasserin |4 aut | |
700 | 1 | |a Koch, Biplob |e verfasserin |4 aut | |
700 | 1 | |a Kumar, Manoj |e verfasserin |4 aut | |
700 | 1 | |a Muthu, Madaswamy S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nanotheranostics |d 2017 |g 8(2024), 2 vom: 12., Seite 179-201 |w (DE-627)NLM268899819 |x 2206-7418 |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2024 |g number:2 |g day:12 |g pages:179-201 |
856 | 4 | 0 | |u http://dx.doi.org/10.7150/ntno.94364 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 8 |j 2024 |e 2 |b 12 |h 179-201 |